Rare hematological diseases fall into many subcategories, including anemia-type red blood cell conditions, white blood cell dysfunctions associated with various malignancies, immuno-disorders, platelet-based abnormalities that affect coagulation, and plasma-based issues (such as hemophilia A and B, von Willebrand disease).
Globally, the Rare Hematology market was estimated at USD XX billion in 2018 and is expected to reach USD XX billion by 2026. The market is large and growing primarily led by Hemophilia.
Global incidence of hemophilia is not well known, but it is estimated that more than 400,000 people are living with hemophilia A and B. However, there is still a substantial unmet need for new therapies that require significantly less frequent infusions and do not promote inhibitor formation.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
